Clinical Trial Update: Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants [Phase 4]

View source ↗

Summary

Phase 4 trial update on immunogenicity and safety of Infanrix Hexa in infants, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Haemophilus Influenzae Type
• Hepatitis B
• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2016-11-30